AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Advanced glycation end-products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose drinking mice

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/138695> since 2016-07-20T15:44:30Z

Published version:

DOI:10.1152/ajpgi.00450.2012

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

**Advanced glycation end-products promote hepatosteatosis by interfering with SCAP-SREBP
pathway in fructose drinking mice**

Raffaella Mastrocola¹, PhD, Massimo Collino², PhD, Mara Rogazzo², PhD student, Claudio Medana³, PhD, Debora Nigro¹, PhD student, Giuseppe Boccuzzi⁴, MD, Manuela Aragno¹, PhD.

Affiliations: ¹Department of Clinical and Biological Sciences, Experimental Medicine and Clinical Pathology Unit, University of Turin, Italy; ²Department of Drug Science and Technology, University of Turin, Turin, Italy; ³Department of Molecular Biotechnology and Life Sciences, University of Turin, Italy; ⁴Oncological Endocrinology, University of Turin, Italy.

Author contribution: experiments planning and manuscript drafting: RM, MA, and GB; animal treatment: RM and MC; analytical chemistry studies: CM; biochemical parameters detection and biomolecular techniques: DN and MR.

Corresponding author:
Raffaella Mastrocola, PhD
Dept. of Clinical and Biological Sciences
Experimental Medicine and Clinical Pathology Unit
University of Turin - C.so Raffaello 30 - 10125 Torino, Italy
Tel: +390116707758 - Fax: +390116707753
E-mail address: raffaella.mastrocola@unito.it

Running head title: AGEs induce SREBP1c activation

35 **Abstract**

36 Clinical studies have linked the increased consumption of fructose to the development of obesity,
37 dyslipidemia and impaired glucose tolerance, and a role in hepatosteatosi s development is
38 presumed. Fructose can undergo a non-enzymatic reaction from which advanced glycation
39 endproducts (AGEs) are derived, leading to the formation of dysfunctional, fructosylated proteins,
40 however the *in vivo* formation of AGEs from fructose is still less known than that from glucose.

41 In the present study C57Bl/6J mice received 15% (w/v) fructose (FRT) or 15% (w/v) glucose
42 (GLC) in water to drink for 30 weeks, resembling human habit to consume sugary drinks. At the
43 end of protocol both FRT and GLC drinking mice had increased fasting glycaemia, glucose
44 intolerance, altered plasma lipid profile, and marked hepatosteatosi s. FRT mice had higher hepatic
45 triglycerides deposition than GLC, paralleled by a greater increased expression and activity of the
46 sterol regulatory element-binding protein 1 (SREBP1), the transcription factor responsible for the
47 *de novo* lipogenesis, and of its activating protein SCAP. LC-MS analysis showed a different pattern
48 of AGEs production in liver tissue between FRT and GLC mice, with larger amount of
49 carboxymethyl lysine (CML) generated by FRT. Double immunofluorescence and
50 coimmunoprecipitation analysis revealed an interaction between CML and SCAP that could lead to
51 prolonged activation of SREBP1.

52 Overall, the high levels of CML and activation of SCAP/SREBP pathway associated to high
53 fructose exposure here reported may suggest a key role of this signaling pathway in mediating
54 fructose-induced lipogenesis.

55
56
57
58

59 **Key words:** AGEs; SREBP; triglyceride synthesis; soft drink; hepatosteatosi s; fructose; glucose;
60 carboxymethyl lysine.

61 **Introduction**

62 Many clinical studies have linked the rising consumption of soft drinks added with fructose to the
63 development of obesity, dyslipidemia, insulin resistance, impaired glucose tolerance, and
64 hypertension in adults (6,9,19, 26). Interestingly, clinical data show that inclusion of fructose in the
65 diet for 10 weeks leads to a greater increase in hepatic lipid synthesis than that occurring with an
66 equal amount of glucose (42).

67 Lipid metabolism is regulated by the sterol regulatory element binding proteins (SREBP) family,
68 comprising three subtypes: SREBP-1a and SREBP-1c, which are generated by alternative splicing,
69 and SREBP-2. SREBP-1c, expressed in most tissues with a greater prevalence than SREBP1a in
70 liver and adrenal glands, is in charge of governing fatty acid and triacylglyceride metabolism, while
71 SREBP-2, ubiquitously expressed, is involved in the regulation of cholesterol metabolism. Both
72 SREBP-1 and SREBP-2 are synthesized as membrane proteins in the endoplasmic reticulum (ER)
73 forming a complex with the SREBP-cleavage activating protein (SCAP). In spite of the distinct
74 roles of the SREBPs in lipid metabolism, they are both subjected to the identical processing
75 pathway (37): when TG or cholesterol synthesis are required, SCAP shuttles SREBPs from the
76 endoplasmic reticulum (ER) to the Golgi, where they are cleaved by two proteases and enter the
77 nucleus, bind to the sterol-regulatory elements in the promoters of target genes and increase
78 transcription of lipogenic or cholesterologenic enzymes (17). Interestingly, SREBP-1 and SREBP-2
79 processing is triggered by different types of stimuli: while SREBP-1 activation depends primarily
80 on insulin signaling and nutritional status, SREBP-2 is sensitive to membrane sterols level (37).

81 The liver is the main organ in which fructose metabolism takes place rapidly leading to increased
82 hepatic synthesis of glycogen, fatty acids and triglycerides (TG) (45). Nonalcoholic fatty liver
83 disease (NAFLD) is the most common disorder in industrialized countries, affecting 15-20% of the
84 general population (49) and epidemiological studies have indicated that the development of NAFLD
85 may be associated with excessive fructose consumption (35,50).

86 Among the chemical properties of fructose, a non-enzymatic pathway known as the Maillard
87 reaction is reported, in which fructose reacts with the aminic groups of proteins. After this reaction,
88 the anomerisation equilibrium of fructose is displaced toward the open form of the sugar, which is
89 highly reactive, especially compared to the forms derived from glucose (43). The Maillard reaction
90 is also one of the “classic” pathways from which the advanced glycation endproducts (AGEs) are
91 derived. It is known that a mixed class of toxic AGEs can be produced from the reduction of
92 glucose (49): CML (carboxymethyl lysine) and pentosidine are obtained through an oxidative
93 process, while MGO (methylglyoxal) and GLAP (glyceraldehyde-derived pyridinium compound)
94 through a non-oxidative process. Additionally, glucose is known to form AGE alpha-oxoaldehydes,
95 including GOLD (glyoxal-lysine dimer) and MOLD (methylglyoxal-lysine dimer), through the
96 polyol pathway (41). AGEs can exert a direct interference with cellular proteins function or a
97 receptor-mediated action, the latter being chiefly attributed to bonding with RAGE (Receptor for
98 AGE) (4). The interaction between AGEs and RAGE leads to intracellular signals responsible for
99 activation of pro-inflammatory transcription factors, such as NFkB (nuclear factor-kB) (3).

100 The Maillard reaction undertaken by fructose leads to the formation of altered, fructosylated
101 proteins, which are potentially toxic, indicating that fructose, together with glucose, plays an
102 important role in the formation of AGEs. So far, the *in vivo* formation of fructose-derived AGEs has
103 only been demonstrated in one study, and only through immunochemical analysis, without
104 reporting a description of their chemical structure (44). Thus, the chemical structure and toxicity of
105 AGEs molecules specifically derived from fructose are less well known than those derived from
106 glucose.

107 It might be hypothesized that the entrance of fructose in hepatocytes, where fructose is metabolized,
108 leads to the fructosylation of cytoplasmic proteins, causing a loss of their functionality and
109 regulation, thus contributing to liver alterations.

110 This study is aimed to characterized fructose-derived AGEs and to investigate their target proteins
111 in liver by a comparative analysis between fructose and glucose-drinking mice.

112 **Materials and Methods**

113 All compounds were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and all primary
114 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), unless otherwise stated.

115 **Animals and treatments**

116 Male C57Bl6/N mice (Charles River Laboratories, Calco, LC, Italy) aged 5 weeks were cared for in
117 compliance with the European Council directives (No. 86/609/EEC) and with the Principles of
118 Laboratory Animal Care (NIH No. 85–23, revised 1985). The scientific project was approved by the
119 local ethical committee. The animals were divided into three groups of 8-10 mice: CTRL-group,
120 drinking tap water; FRT-group, drinking a 15% fructose solution; GLC-group, drinking a 15%
121 glucose solution. All groups were fed with a standard lab chow and received drink and food *ad*
122 *libitum*.

123 Body weight, drink and food intake were recorded weekly. Fasting glycemia was measured at the
124 start of the protocol and every 8 weeks by saphenous vein puncture using a glucometer
125 (GlucoGmeter, Menarini Diagnostics, Firenze, Italy). After 30 weeks mice were anesthetized and
126 killed by cardiac exsanguination. Blood was collected and plasma isolated. The liver was rapidly
127 removed. A portion was cryoprotected in OCT (Optimal Cutting Temperature) compound (VWR,
128 Milano, Italy) and frozen in N₂ for cryostatic preparations. Other portions were frozen in N₂ and
129 stored at –80°C for protein analysis.

130 **Oral glucose tolerance test**

131 Before killing, a glucose solution was administered orally at 2 g/kg b.w after a fasting period of 6 h.
132 Plasma glucose levels were measured every 30 minutes for 2 hrs after glucose loading.

133 **Biochemical parameters**

134 Plasma lipid profile was determined by standard enzymatic procedures using reagent kits
135 (triglycerides (TG), cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL):
136 Hospitex Diagnostics, Florence, Italy; non-esterified fatty acid (NEFA): Wako Chemicals,Neuss,
137 Germany).

138 Plasma insulin level was measured using an enzyme-linked immunosorbent assay (ELISA) kit
139 (Mercodia AB, Uppsala, Sweden).

140 For tissue TG and cholesterol content determination, colorimetric assay kits were used after lipid
141 extraction (TG: Triglyceride Quantification Kit, Abnova Corporation, Aachen, Germany;
142 cholesterol: Hospitex Diagnostics).

143 **Oil red staining**

144 Liver lipid accumulation was evaluated by oil red staining on 4 μ m cryostatic sections. Stained
145 tissues were viewed under an Olympus Bx4I microscope (10x magnification) with an
146 AxioCamMR5 photographic attachment (Zeiss, Gottingen, Germany). The sections were analyzed
147 on six fields/slide and scored by a blinded pathologist using the NAFLD activity score (NAS)
148 system (21).

149 **Preparation of tissue extracts**

150 Liver cytosolic, nuclear, and total proteins were extracted as previously described (28). Protein
151 content was determined using the Bradford assay and samples were stored at -80°C until use.

152 **AGEs analysis with LC-MS**

153 Pentosidine, GOLD, MOLD, CML, and GLAP, were evaluated on total liver extracts after
154 hydrolysis with 0.6 M trichloroacetic acid and 50 μ L of hydrochloric acid 6 M for 12 hours at 60°C.
155 The chromatographic separations were run on an Ultimate 3000 HPLC (Dionex, Milan, Italy)
156 coupled to a high resolving power mass spectrometer (HRMS) LTQ Orbitrap (Thermo Scientific,
157 Rodano, Italy), equipped with an atmospheric pressure interface and an ESI ion source. The
158 samples were analyzed using an Reverse Phase C18 column (Phenomenex Synergi 150 $\times$ 2.1 mm, 3
159 μ m particle size) at a flow rate of 200 μ L/min. A gradient mobile phase composition was adopted:
160 95/5 to 40/60 in 25 min, 5 mM heptafluorobutanoic acid/acetonitrile. The monitored protonated
161 molecular ions were 205.1188 m/z for CML, 255.1344 m/z for GLAP, 341.2189 m/z for MOLD,
162 327.2032 m/z for GOLD and 379.2094 m/z for pentosidine. Quantitative determination of all the
163 analytes were done by using pentosidine calibration data.

164 **Western blotting.**

165 Equal amounts of total, cytosolic or nuclear proteins were separated by SDS-PAGE and
166 electrotransferred to nitrocellulose membrane (GE-Healthcare Europe, Milano, Italy). Mouse anti-
167 NFkBp65, rabbit anti-SREBP1 and mouse anti-SREBP2 antibodies were probed on both cytosolic
168 and nuclear extracts. Goat anti-ICAM-1 (intercellular adhesion molecule-1) and anti-CTGF
169 (connective tissue growth factor), rabbit anti-SCAP, anti-ACC (Cell Signaling Technology, Danver,
170 MA,USA), anti-HMGR (Millipore, Temecula, CA, USA), anti-apoB, anti-CPT1-L, and anti-RAGE
171 were probed on total extracts. Rabbit anti-apoB was also probed on 10 ul of plasma samples.
172 Proteins were detected with ECL chemiluminescence substrate (GE-Healthcare) and quantified by
173 densitometry using analytic software (Quantity-One, Bio-Rad). β -actin served as loading control for
174 total and cytosolic protein extracts, and lamin-B1 for nuclear extracts.

175 **Immunofluorescence**

176 Localization of SCAP, SREBP1, CML and MGO was assessed on 4 μ m liver cryostatic sections by
177 indirect immunofluorescence. Sections were blocked for 1 h with 3% BSA in PBS added with
178 unconjugated goat anti-mouse IgG to prevent mouse-on-mouse interferences. Thus, sections were
179 incubated overnight with rabbit anti-SCAP, rabbit anti-SREBP1, mouse anti-CML (Trans-Genic,
180 Kobe, Japan) or mouse anti-MGO (Trans-Genic) primary antibodies and for 1 h with fluorescent
181 secondary antibodies (Dako, Glostrup, Denmark): TRITC-conjugated anti-rabbit IgG or biotin-
182 conjugated anti-mouse IgG followed by FITC-conjugated streptavidin. Negative controls were
183 prepared incubating sections with secondary antibodies. Sections were examined using a Leica
184 Olympus epifluorescence microscope (Olympus Bx4I) and digitised with a high resolution camera
185 (Zeiss).

186 **Double immunofluorescence.**

187 Double immunofluorescence was performed for SCAP and CML on liver cryostatic sections. After
188 blocking, sections were incubated with a mix of primary antibodies for 1 hour. After washing,
189 sections were incubated with a mix of labelled secondary antibodies. The images were colour-

190 combined and assembled into photomontages by using Adobe Photoshop (Universal Imaging, West
191 Chester, PA).

192 **Co-immunoprecipitation.**

193 Equal amounts of total proteins (500 µg) were incubated overnight with SCAP rabbit-polyclonal
194 antibody (2 µg). The antibody-antigen complexes were then incubated with fresh Protein A
195 Sepharose beads for 3 h. SDS Laemmli buffer was added to the beads and eluted proteins were
196 subjected to SDS-PAGE and immunoblotted with mouse anti-CML monoclonal antibody and, after
197 stripping, with rabbit anti-SCAP antibody.

198 **Statistical analysis**

199 All values are expressed as means ± SD and were analyzed by Anova test followed by Bonferroni's
200 post-test. A *P* value <0.05 was considered statistically significant.

201 **Results**

202 **Fructose and glucose drinking in mice induces alterations in body weight, glucose tolerance** 203 **and plasma lipid profile.**

204 The daily drink intake in the FRT and GLC drinking groups was markedly higher than in the CTRL
205 group, drinking tap water. Moreover, GLC intake was also significantly higher than FRT, but
206 despite that, the total daily caloric intake was similar among the groups, being proportionally
207 reduced the food intake (**Table 1**).

208 As shown in **Table 1**, mice drinking FRT or GLC for 30 weeks showed a significant increase in
209 body weight compared to CTRL mice (+31%).

210 Fasting glycemia was significantly higher both in FRT and in GLC groups compared to CTRL
211 group (**Table 1**). During OGTT (**Fig. 1A**), the glycemic curves of FRT and GLC mice were
212 markedly moved away from CTRL curve at every time-point after glucose charge. Plasma insulin
213 level was slightly increased in GLC group and in a greater extent in FRT group, with respect to
214 CTRL, without reaching any statistical significance (**Table 1**).

215 In comparison with CTRL animals, FRT mice showed alterations in plasma lipid profile (**Table 2**)
216 featured by increased levels of TG (+43%), cholesterol (+37%), and LDL (+80%), paralleled by a
217 decrease in NEFA (-24%). GLC mice only showed a trend to dyslipidemia that didn't reach the
218 statistical significance, excepting for HDL level (-16%), and for NEFA level that, conversely to
219 FRT group, was increased (+20%) compared to CTRL.

220 **Fructose and glucose drinking increases liver TG and cholesterol content and induces**
221 **hepatosteatosi.**

222 Hepatic homogenates of FRT mice showed a marked increase in TG and cholesterol content
223 compared to CTRL (+100% and +50%, respectively). In liver homogenates from GLC mice an
224 increase in cholesterol content similar to FRT was found (+42% of the CTRL value), while the TG
225 level tend to increase compared to CTRL, but remained significantly lower than in FRT group (-
226 60%) (**Fig. 1B**).

227 Oil red staining of liver sections (**Fig. 1C-E**) highlighted a marked lipid deposition both in FRT (**D**)
228 and in GLC mice (**E**) compared to CTRL (**C**), resembling a condition of non-alcoholic fatty liver
229 disease, with different histopathological features. FRT mice liver showed enlarged hepatocytes with
230 periportal macrovacuolar steatosis. In contrast, liver of GLC mice showed a microvesicular steatosis
231 with a panlobular dissemination. A significantly higher steatosis grade was detected in FRT
232 compared to GLC mice, conferring an overall NAS score of 5.2 ± 1.3 to FRT vs. 3.8 ± 0.9 to GLC
233 mice liver ($P < 0.05$) (**Fig. 1F**).

234 **Fructose and glucose drinking enhances TG and cholesterol synthesis through activation of**
235 **SCAP-SREBP signalling.**

236 To further investigate the greater lipogenic effect of FRT with respect to GLC, we assessed the
237 expression and activation of SREBP1c, SREBP2 and their activating protein SCAP by western
238 blotting analysis (**Fig. 2**).

239 SCAP was markedly up-regulated in FRT and GLC mice compared to CTRL (**Fig. 2A,B**), in a
240 significantly greater extent in FRT than in GLC. Both SREBP1c and SREBP2 were up-regulated in

241 FRT and GLC groups compared to CTRL (**Fig. 2C-H**). Specifically, the 68 kDa active form (**Fig.**
242 **2C,E**) and the 125 kDa inactive form (**Fig. 2F,H**) of SREBP1c were significantly more expressed in
243 liver of FRT mice than in GLC. In contrast, SREBP2 was equally activated in FRT and GLC liver
244 (**Fig. 2D,E**), while inactive form of SREBP2 was more expressed in GLC liver than in FRT,
245 without reaching significant difference (**Fig. 2G,H**). The activation of the SCAP/SREBP pathway
246 is confirmed by the increased expression in FRT and GLC mice liver of both the SREBP1c target
247 gene encoding acetyl coenzyme A carboxylase (ACC), one of the enzymes that promote triglyceride
248 synthesis, (**Fig. 3A,B**), and the SREBP2 target gene encoding hydroxymethyl coenzyme A
249 reductase (HMGR), the rate limiting enzyme of the cholesterol synthesis (**Fig. 3C,D**). Notably, the
250 expression of ACC is about 35% greater in FRT than in GLC mice liver (**Fig. 3B**) according to the
251 higher activation of SREBP1c.

252 ApoB100 protein level was measured in plasma and liver as marker of VLDL secretion (**Fig. 3E**),
253 while the expression of carnitine palmitoyl transferase 1 (CPT1-L) (**Fig. 3G**) indicates the
254 efficiency of β -oxidation. Any significant differences were seen in ApoB100 plasma-to-liver
255 protein level (**Fig. 3F**) and in liver expression of CPT1-L (**Fig. 3H**), among the three groups,
256 although a trend to a reduction of CPT1-L level was seen in GLC mice.

257 **Fructose and glucose drinking enhances AGEs generation and activates RAGE signalling.**

258 As shown in **Table 3**, all AGEs here measured were markedly increased in liver homogenates of
259 FRT and GLC mice compared to CTRL. Most notably, GLAP and MOLD highest levels were
260 detected in the liver of GLC-drinking group, while GOLD and CML were produced in the greatest
261 amount in the liver from FRT group (**Table 3**). The receptor for AGEs, RAGE, was up-regulated
262 both in FRT and GLC mice compared to CTRL (+100%) (**Fig. 4A,B**) and the downstream
263 signalling was activated as demonstrated by the nuclear translocation of NFkB-p65 (**Fig. 4C,D**). As
264 consequence, we found increased levels of the NF-kB-dependent protein ICAM-1 in both sugar-
265 drinking groups (**Fig. 4E,F**), and a slight, but not significant, increase of an early marker of fibrosis,

CTGF (**Fig. 4E,F**), even if morphological signs, as collagen I and IV deposition, were still not detectables (data not shown).

CML colocalizes with SCAP in liver of fructose drinking mice.

Immunofluorescence analysis on liver sections from FRT mice showed a prevalent nuclear localization for SREBP1c (**Fig. 5A,B**), consistent with its activation, and a cytosolic perinuclear localization for SCAP (**Fig. 5D,E**). CML localized mainly in cytosol of hepatocytes (**Fig. 5G,H**), with a perinuclear distribution similar to SCAP. Interestingly, MGO was detected mainly in the endothelium and at the plasmamembrane of hepatocytes (**Fig. 5J,K**).

Double immunofluorescence studies in liver of FRT group confirmed that CML colocalizes with SCAP in the perinuclear zone of the hepatocytes (**Fig. 6A-F**).

CML modifies SCAP in liver of fructose drinking mice.

Finally, co-immunoprecipitation assay has been performed to evaluate SCAP glycosylation by CML (**Fig. 6G,H**). SCAP was immunoprecipitated with Protein A Sepharose, electrophoresed and blotted on nitrocellulose membrane. Membrane was then exposed to CML antibody, revealing a complex between SCAP and CML in liver of FRT mice.

Discussion

This study clearly demonstrates a significant activation of SCAP/SREBP pathway and the following increase in *de novo* lipogenesis, which were associated to high levels of fructose-derived AGEs in the liver of mice chronically exposed to high fructose intake.

Reducing sugars, as fructose and glucose, react spontaneously with amino groups of proteins to advanced glycation end products (AGEs) (27). Although glucose plays a primary role in the formation of AGEs, it is now known that fructose undergoes the same non-enzymatic glycation reaction at a much faster rate. When fructose assumption with foods or beverages is remarkable, its high reactivity may substantially contribute to the tissue formation of AGEs and lead to cellular alterations and dysfunction (38).

291 Our study shows for the first time a different pattern of hepatic AGEs between FRT and GLC
292 detected by LC-MS. In detail, FRT generates higher levels of AGEs derived from glyoxal, such as
293 GOLD and CML, while we found more AGEs derived from methylglyoxal, MOLD and GLAP, in
294 GLC mice. These differences may just reflect the dissimilar pathways and rates of FRT and GLC
295 metabolism. Moreover, methylglyoxal is less toxic toward hepatocytes than glyoxal being a better
296 substrate for the carbonyl detoxifying enzymes, while the rate of metabolism of glyoxal by
297 hepatocyte metabolizing enzymes is much faster than for methylglyoxal (39). This could account
298 for the greater accumulation of GOLD and CML in FRT mice.

299 So far there are limited data directly comparing the effects of fructose and glucose *in vivo* on lipid
300 metabolism, the few existing using very high concentration of sugars for a short time (22,40,42,48),
301 and even less on AGEs generation (1,27).

302 For this reason, the peculiarities of the present study are the characterization of *in vivo* AGEs
303 generation from fructose and the suggestion of their involvement in the increased hepatic lipid
304 synthesis, in comparison with glucose, through an experimental protocol based on low sugar
305 concentrations given for a long time, mimicking the diffused human habit to daily drink sweetened
306 beverages.

307 In physiological conditions, the potential sources of TG that contribute to fatty liver development
308 are NEFA coming from the hydrolysis of fatty acids stored in adipose tissue, dietary fatty acids and
309 newly synthesized fatty acids through *de novo* lipogenesis (11). Moreover, an impairment of the
310 lipid β -oxidation rate or of the hepatic triglycerides clearance by VLDL may also lead to hepatic
311 lipid accumulation (46). In the present study FRT drinking mice had lower plasma NEFA than GLC
312 mice, while both the liver expression of CPT-1, the rate limiting enzyme of mitochondrial β -
313 oxidation, and the ratio between plasma and liver levels of ApoB100, the structural component of
314 VLDL, did not differ in FRT and GLC mice. These data indicate for the first time that the *de novo*
315 synthesis is the main pathway responsible for the higher lipid accumulation in liver of FRT mice

316 with respect to GLC, in which other mechanisms, such as reduction of β -oxidation and higher
317 hydrolysis of adipose fat, may contribute to hepatic steatosis, as previously suggested by other
318 authors (30).

319 Liver is the main tissue involved in fructose handling and *de novo* lipogenesis (18), and many
320 studies have shown that fructose plays a specific role in the pathogenesis of hepatosteatosis and
321 metabolic syndrome due to differential hepatic fructose metabolism (25,32,33). However, the
322 molecular mechanisms by which high fructose diets induce abnormalities in liver TG metabolism
323 are not fully understood.

324 It has been observed that a simultaneous induction of glycolytic and lipogenic genes is a salient
325 feature when dietary glucose is replaced with fructose. Indeed, fructose ingestion at high doses
326 increases expression of the genes encoding for lipogenic enzymes via the activation of SREBP1 in
327 the liver (29). Thus, we have analyzed the expression of SREBP1c, SREBP2 and of their chaperone
328 protein SCAP in the liver of FRT and GLC drinking mice.

329 In our work, chronic exposure to low levels of both FRT and GLC induced the activation of the
330 SCAP/SREBP system. Notably, there was a marked difference in SCAP expression between FRT
331 and GLC mice, being higher in FRT, and this could be crucial for the greater induction of
332 lipogenesis by fructose. Indeed, we observed a significantly higher expression and activation of
333 SREBP1c in liver of FRT versus GLC mice, as confirmed by the resulting higher expression of
334 ACC and by the greater hepatic TG accumulation. On the other hand, SREBP2 is equally
335 hyperactivated in FRT and GLC mice, leading thus to similar expression of HMGR and thereby to
336 similar level of cholesterol in liver. Although SCAP is the common activating protein of both
337 SREBP1c and SREBP2, the existence of unidentified regulatory factors, such as nutritional status or
338 food composition, that determine the fate of the SREBP/SCAP complex by distinguishing between
339 SREBP-1c and SREBP-2 processing, has been supposed (17,37).

340 Insulin is a well-known inducer of SREBP1c activity and hyperinsulinemia may contribute in
341 hyperactivation of lipogenic pathway (7,8). However, in our experimental model FRT and GLC

342 mice, even showing altered glucose homeostasis, didn't reach a condition of hyperisulinemia
343 adequate to induce the *de novo* lipogenesis.

344 We then hypothesized a possible interference of CML on SCAP/SREBP system. Indeed, a direct
345 correlation between AGEs serum level and triglyceride level was found in children and adolescent
346 with Type I diabetes (13). Besides, the generation of CML has been observed during high fat/high
347 sugar diets (20,36) and this has been attributed to lipid peroxidation processes (12). A relationship
348 between intracellular lipid accumulation and increase in CML levels has also been recently
349 demonstrated in an *in vitro* model of steatosis (12). Moreover, CML accumulation in the liver of
350 obese individuals has been involved in hepatosteatosis development (41). This is also supported by
351 a study showing that administration of pyridoxamine, an inhibitor of CML formation, reduces
352 plasma triglyceride and cholesterol on Zucker obese rats (2).

353 Several studies have indicated that interaction of CML with RAGE causes oxidative stress and
354 activation of NFkB via multiple intracellular signal pathways (5,16). Our results demonstrated that
355 both FRT- and GLC-chronic exposure increased hepatic RAGE expression, and consequently
356 activates NFkB and inflammatory/fibrogenic signaling, at the same level. Therefore, the CML
357 involvement in the higher lipogenesis occurring in FRT mice is not mediated by RAGE binding.

358 A recent *in vitro* study in cultured mesangial cells highlights a direct causal role for CML in
359 SREBPs activation by interfering with SCAP and thus driving SREBPs factors to elude its negative
360 feedback control (52). The glycosylation of SCAP by Golgi enzymes plays an important role in the
361 cycling of SCAP between the ER and the Golgi (31,51). In physiological conditions, high
362 intracellular concentrations of cholesterol prevent transport of the SCAP-SREBP complex from the
363 ER to the Golgi and downregulate SREBPs activation avoiding intracellular cholesterol and lipids
364 overloading (10). CML administration in mesangial cells disrupted the SCAP-mediated feedback
365 regulation of SREBPs, increasing SCAP gene transcription and protein stability, thereby enhancing
366 the cycling of SCAP between the ER and the Golgi and prolonging SREBPs activation (52).

367 Consistently, our immunofluorescence analysis suggested an interaction between CML and SCAP

368 which were extensively colocalized in the perinuclear zone of the hepatocytes in FRT mice. The
369 result of coimmunoprecipitation technique further reinforced our hypothesis of a cross-link between
370 CML and SCAP, indicating for the first time that a specific interference of CML in SCAP/SREBP
371 system occurs also *in vivo* and, most notably, could be induced by FRT drinking. However, further
372 experiments with specific CML inhibitors are needed for a conclusive demonstration of the causal
373 role of fructose-derived AGEs in the activation of this specific signaling pathway. Recently, uric
374 acid that generates from fructose metabolism has been suggested as a further mechanism
375 contributing at least in part to the lipogenic effect of fructose feeding (23,24). Uric acid has been
376 shown to induce mitochondrial oxidative stress and accumulation of citrate being the substrate for
377 the *de novo* lipogenesis (23). It is known that oxidative stress is an important element in the
378 glycoxidation process that leads to AGEs accumulation (15) and in some cases a direct positive
379 correlation between uric acid and pentosidine levels has been reported (14,34).

380 In summary, the present results improve our knowledge on fatty liver development and show an
381 association between high levels of fructose-derived AGEs and activation of *de novo* lipogenesis,
382 thus suggesting more caution in the even wider employment of fructose as added sweetener in foods
383 and beverages.

384 **Grants**

385 This study was supported by a grant of CRT Foundation (2010.1954): “Consuming of sugar-added
386 drinks as risk factor for metabolic diseases: emerging role of fructose” and by MIUR, Fondi ex-
387 60%: “High fructose intake: sweetener or health detrimental?”.

388 **Disclosures**

389 No conflict of interest, financial or otherwise, are declared by the authors.

390

391

392

393

394 **References**

- 395 1) Ahmed N, Furth AJ. Failure of common glycation assays to detect glycation by fructose. *Clin*
396 *Chem* 38(7): 1301-3, 1992.
- 397 2) Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW.
398 The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular
399 disease in Zucker obese rats. *Kidney Int* 63(6): 2123-33, 2003.
- 400 3) Aragno M, Mastrocola R, Medana C, Restivo F, Catalano MG, Pons N, Danni O, Boccuzzi G.
401 Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented
402 by antioxidant treatment. *Endocrinology* 146: 5561-5567, 2005.
- 403 4) Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth
404 PP. Understanding RAGE, the receptor for advanced glycation end products. *J Mol Med* 83:
405 876-86, 2005.
- 406 5) Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney.
407 *Am J Physiol Renal Physiol* 289: F645-59, 2005.
- 408 6) Bray GA. Soft drink consumption and obesity: it is all about fructose. *Curr Opin Lipidol* 21:
409 51-57, 2010.
- 410 7) Brown MS, Goldstein JL. Selective versus total insulin resistance. *Cell Metab* 7:95–96, 2008.
- 411 8) Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic
412 steatosis, and insulin resistance. *Trends Endocrinol Metab* 22: 353–363, 2011.
- 413 9) Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin
414 resistance syndrome. *Am J Clin Nutr* 76: 911-22, 2002.
- 415 10) Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. *Annu Rev Genet* 41:
416 401-27, 2007.
- 417 11) Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor
418 SREBP-1c. *Diabetes Obes Metab* 2: 83-92, 2010.

- 419 12) Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JW, Driessen A, Wolfs MG, Hofker
420 MH, Bloemen JG, Dejong CH, Stehouwer CD, Schalkwijk CG. Endogenous formation of Nε-
421 (carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in
422 vitro model of hepatic steatosis. *J Hepatol* 56: 647-55, 2012.
- 423 13) Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G. Impact of metabolic control
424 and serum lipids on the concentration of advanced glycation end products in the serum of
425 children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and
426 nephsilon-(carboxymethyl)lysine ELISA. *Diabetes Care* 26(9):2609-15, 2003.
- 427 14) Germanová A, Koucký M, Hájek Z, Parížek A, Zima T, Kalousová M. Soluble receptor for
428 advanced glycation end products in physiological and pathological pregnancy. *Clin Biochem*
429 43(4-5): 442-6, 2010.
- 430 15) Giacco F, Brownlee M. Oxidative stress and diabetic complications. *Circ Res* 107(9): 1058-70,
431 2010.
- 432 16) Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products:
433 sparking the development of diabetic vascular injury. *Circulation* 114: 597-605, 2006.
- 434 17) Goldstein JL, Bose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell* 124: 35–
435 46, 2006.
- 436 18) Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans.
437 *Annu Rev Nutr* 16: 523–557, 1996.
- 438 19) Hofmann SM and Tschop MH. Dietary sugars: a fat difference. *J Clin Invest* 119: 1089-1092,
439 2009.
- 440 20) Kanner J. Dietary advanced lipid oxidation endproducts are risk factors to human health. *Mol*
441 *Nutr Food Res* 51: 1094-101, 2007.
- 442 21) Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu
443 YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic

- 444 Steatohepatitis Clinical Research Network. Design and validation of a histological scoring
445 system for nonalcoholic fatty liver disease. *Hepatology* 41: 1313–1321, 2005.
- 446 22) Koo HY, Miyashita M, Cho BH, Nakamura MT. Replacing dietary glucose with fructose
447 increases ChREBP activity and SREBP-1 protein in rat liver nucleus. *Biochem Biophys Res*
448 *Commun* 390(2): 285-9, 2009.
- 449 23) Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA,
450 Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang
451 DH, Sautin YY, Johnson RJ. Uric acid induces hepatic steatosis by generation of mitochondrial
452 oxidative stress: potential role in fructose-dependent and -independent fatty liver. *J Biol Chem*
453 287(48): 40732-44, 2012.
- 454 24) Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, Le M,
455 Garcia GE, Thomas JB, Rivard CJ, Andres-Hernando A, Hunter B, Schreiner G, Rodriguez-
456 Iturbe B, Sautin YY, Johnson RJ. Uric acid stimulates fructokinase and accelerates fructose
457 metabolism in the development of fatty liver. *PLoS One* 7(10): e47948, 2012.
- 458 25) Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the
459 pathogenesis of NAFLD and the metabolic syndrome. *Nat Rev Gastroenterol Hepatol* 7(5):
460 251-64, 2010.
- 461 26) Madero M, Perez-Pozo SE, Jalal D, Johnson RJ, Sanchez-Lozada LG. Dietary fructose and
462 hypertension. *Curr Hypertens Rep* 13: 29–35, 2011.
- 463 27) Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced
464 glycosylation end products in vivo. *J Biol Chem* 267: 5133-8, 1992.
- 465 28) Mastrocola R, Guglielmotto M, Medana C, Catalano MG, Cutrupi S, Borghi R, Tamagno E,
466 Boccuzzi G, Aragno M. Dysregulation of SREBP2 induces BACE1 expression. *Neurobiol Dis*
467 44: 116-24, 2011.
- 468 29) Mori T, Kondo H, Hase T, Murase T. Dietary phospholipids ameliorate fructose-induced
469 hepatic lipid and metabolic abnormalities in rats. *J Nutr* 141: 2003-9, 2011.

- 470 30) Ngo Sock ET, Lê KA, Ith M, Kreis R, Boesch C, Tappy L. Effects of a short-term overfeeding
471 with fructose or glucose in healthy young males. *Br J Nutr* 103(7): 939-43, 2010.
- 472 31) Nohturfft A, Bose-Boyd RA, Scheek S, Goldstein JL, Brown MS. Sterols regulate cycling of
473 SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. *PNAS*
474 96: 11235–11240, 1999.
- 475 32) Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic
476 fatty liver disease. *J Nutr Biochem* 23:203-8, 2012.
- 477 33) Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease.
478 *World J Gastroenterol* 16: 2579-88, 2010.
- 479 34) Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G. Plasma advanced glycosylation end-
480 products in maintenance haemodialysis patients. *Nephrol Dial Transplant* 10(11): 2110-3,
481 1995.
- 482 35) Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek
483 MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol* 48:
484 993-9, 2008.
- 485 36) Ruiz-Ramírez A, Chávez-Salgado M, Peñeda-Flores JA, Zapata E, Masso F, El-Hafidi M.
486 High-sucrose diet increases ROS generation, FFA accumulation, UCP2 level, and proton leak
487 in liver mitochondria. *Am J Physiol Endocrinol Metab* 301: E1198-207, 2011.
- 488 37) Sato R, Sterol metabolism and SREBP activation. *Archives of Biochemistry and Biophysics*
489 501: 177–181, 2010
- 490 38) Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic
491 glycation: sweet coupling or bad modification. *Diabetes Metab Res Rev* 20: 369-82, 2004.
- 492 39) Shangari N, Poon R, O'Brien PJ. Hepatocyte methylglyoxal (MG) resistance is overcome by
493 inhibiting aldo-keto reductases and glyoxalase I catalysed MG metabolism. *Enzymol Mol Biol*
494 *Carbonyl Metab* 12: 266-275, 2006.

- 495 40) Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Häring HU, Fritsche A. Effects of 4-
496 week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids:
497 an exploratory trial. *Br J Nutr* 106(1): 79-86, 2011.
- 498 41) Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review.
499 *Diabetologia* 44: 129-46, 2001.
- 500 42) Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox
501 CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M,
502 Otokozawa S, Nakajima K, Nakano T, Beyesen C, Hellerstein MK, Berglund L, Havel PJ.
503 Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity
504 and lipids and decreases insulin sensitivity in overweight/obese humans. *J Clin Invest* 119:
505 1322-1334, 2009.
- 506 43) Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine
507 serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by
508 glucose. *J Biol Chem* 264: 3674-3679, 1989.
- 509 44) Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi S.
510 Immunological detection of fructose-derived advanced glycation end-products. *Lab Invest* 90:
511 1117-27, 2010.
- 512 45) Tappy L and Lê KA. Metabolic effects of fructose and the worldwide increase in obesity.
513 *Physiol Rev* 90: 23-46, 2010.
- 514 46) Tappy L, Lê KA. Does fructose consumption contribute to non-alcoholic fatty liver disease?
515 *Clin Res Hepatol Gastroenterol* 36(6): 554-60, 2012.
- 516 47) Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of
517 cardiovascular disease: the plot thickens. *Diabetologia* 51: 444-50, 2008.
- 518 48) Teff KL, Grudziak J, Townsend RR, Dunn TN, Grant RW, Adams SH, Keim NL, Cummings
519 BP, Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming fructose- and

glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. *J Clin Endocrinol Metab* 94(5): 1562-9, 2009.

49) Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. *Biochem J* 375: 581-92, 2003.

50) Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, Maier KP, Bischoff SC, Bergheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. *J Nutr* 138: 1452-5, 2008.

51) Velasco A, Hendricks L, Moremen KW, Tulsiani DR, Touster O, Farquhar MG. Cell type-dependent variations in the subcellular distribution of alpha-mannosidase I and II. *J Cell Biol* 122: 39–51, 1993.

52) Yuan Y, Zhao L, Chen Y, Moorhead JF, Varghese Z, Powis SH, Minogue S, Sun Z, Ruan XZ. Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. *Am J Physiol Renal Physiol* 301: F236-43, 2011.

545 **Figure captions**

546 **Fig. 1. FRT and GLC drinking affect glycaemic control and liver lipid accumulation.** (A) Oral
547 glucose tolerance test performed on 6 hrs fasting mice after 30 weeks of water, FRT or GLC
548 drinking. (B) TG and cholesterol content in mice liver. (C-E) Representative 20x magnification
549 photomicrographs of oil red staining on liver sections from CTRL (C), FRT (D), and GLC (E) mice.
550 (F) Pathological grading in liver sections from CTRL, FRT and GLC mice according to the NAFLD
551 activity score system by Kleiner et al. (21). Data are means $\pm$ S.D. of 8-10 mice per group. * P <0.05,
552 ** P <0.01 vs CTRL; † P <0.05 vs FRT.

553
554 **Fig. 2. Expression analysis on SCAP/SREBP pathway.** Western blotting analysis for SCAP (A),
555 nuclear active SREBP1c (C) and SREBP2 (D), cytosolic inactive SREBP1c (F) and SREBP2 (G).
556 (B,E,H) Histograms report densitometric analysis of 6-8 mice per group. * P <0.05, ** P <0.01,
557 *** P <0.005 vs CTRL; † P <0.05 vs FRT.

558
559 **Fig. 3. Expression analysis on markers of synthesis, β -oxidation and secretion of hepatic**
560 **lipids.** Western blotting analysis for ACC (A), HMGR (C), ApoB100 (E) and CPT1-L (G).
561 (B,D,F,H) Histograms report densitometric analysis of 6-8 mice per group. ** P <0.01, *** P <0.005
562 vs CTRL; † P <0.05 vs FRT.

563
564 **Fig. 4. Expression analysis on RAGE/NFkB pathway.** Representative western blotting analysis
565 on total liver extracts for RAGE(A), on nuclear and cytosolic liver extracts showing NFkB
566 activation (C), on total liver extracts for ICAM-1 and CTGF (E). (B,D,F) Histograms report
567 densitometric analysis of 6-8 mice per group. * P <0.05, ** P <0.01 vs CTRL.

568
569 **Fig. 5. Liver localization of SREBP1c, SCAP, CML, and MGO.** Representative 40x/100x
570 magnification photomicrographs of immunofluorescence analysis for SREBP1c (A,B), SCAP

571 (D,E), CML (G,I) and MGO (J,K) on 4μm cryostatic liver sections. To assess aspecific staining,
572 negative controls were prepared incubating sections only with secondary antibodies (anti-rabbit:
573 C,F; anti-mouse: I,L).

574

575 **Fig. 6. CML interaction with SCAP.** (A-F) Representative photomicrographs of double
576 immunofluorescence for SCAP/CML. SCAP (A,D) was revealed by red fluorescence and CML
577 (B,E) was revealed by green fluorescence. Colocalization is shown in merged images (C,E). (G)
578 Immunoprecipitation studies on liver extracts. SCAP has been immunoprecipitated (IP) and
579 membranes were incubated (IB) with anti-CML or anti-SCAP antibodies. (H) Histogram represent
580 CML to SCAP band density ratio obtained by densitometric analysis of immunoprecipitation
581 studies performed on 5-6 mice per group. Data are means ± S.D. Statistical significance: * $P < 0.05$
582 vs CTRL; † $P < 0.05$ vs FRT.

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597 **Table 1. General parameters of mice after 30 weeks drinking water, FRT or GLC.** Data are
 598 means $\pm$ S.D. of 8-10 mice per group. * $P<0.05$, ** $P<0.01$, *** $P<0.005$ vs CTRL; ††† $P<0.005$ vs
 599 FRT.

	CTRL	FRT	GLC
Drink intake (ml/die)	3.7 $\pm$ 0.4	6.5 $\pm$ 0.5***	11.4 $\pm$ 3.8***†††
Food intake (g/die)	3.8 $\pm$ 0.9	2.6 $\pm$ 0.6*	2.0 $\pm$ 0.9**
Caloric intake (Kcal/die)	11.1 $\pm$ 2.8	11.3 $\pm$ 1.8	12.4 $\pm$ 2.1
Body weight increase (g)	12.4 $\pm$ 2.0	16.3 $\pm$ 2.5***	16.2 $\pm$ 2.4***
Fasting glycemia (mmol/l)	4.7 $\pm$ 1.0	7.2 $\pm$ 1.5**	7.1 $\pm$ 0.9***
Insulinemia (μ g/l)	1.27 $\pm$ 0.07	2.13 $\pm$ 1.02	1.68 $\pm$ 1.03

615 **Table 2. Plasma lipid profile of mice after 30 weeks of water, FRT or GLC drinking.** Data are
 616 means $\pm$ S.D. of 8-10 mice per group. * P <0.05, ** P <0.01, *** P <0.005 vs CTRL; $\dagger\dagger P$ <0.01 vs
 617 FRT.

	CTRL	FRT	GLC
TG (mmol/l)	1.12 $\pm$ 0.18	1.60 $\pm$ 0.28**	1.34 $\pm$ 0.33
Cholesterol (mmol/l)	2.26 $\pm$ 0.20	3.10 $\pm$ 0.36***	2.68 $\pm$ 0.63
HDL (mmol/l)	1.46 $\pm$ 0.23	1.31 $\pm$ 0.24	1.23 $\pm$ 0.12*
LDL (mmol/l)	0.80 $\pm$ 0.17	1.44 $\pm$ 0.44**	0.95 $\pm$ 0.31
NEFA (mg/dl)	12.76 $\pm$ 1.58	9.75 $\pm$ 2.08**	15.29 $\pm$ 3.36* $\dagger\dagger$

618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633

634 **Table 3. Advanced glycated end-products evaluated by LC-MS in liver homogenates.** Data are
 635 means $\pm$ S.D. of 8-10 mice per group. * $P<0.05$, ** $P<0.01$, *** $P<0.005$ vs CTRL; † $P<0.05$,
 636 †† $P<0.01$, ††† $P<0.005$ vs FRT.

	CTRL	FRT	GLC
Pentosidine (pg/mg prot)	n.d.	7.02 $\pm$ 3.98*	8.69 $\pm$ 0.92***
GLAP (ng/mg prot)	n.d.	0.36 $\pm$ 0.09*	2.20 $\pm$ 0.86*†
GOLD (ng/mg prot)	n.d.	148.1 $\pm$ 53.7**	98.5 $\pm$ 30.0**
MOLD (ng/mg prot)	n.d.	0.37 $\pm$ 0.24*	1.08 $\pm$ 0.11***††
CML (ng/mg prot)	0.57 $\pm$ 0.09	1.34 $\pm$ 0.14***	0.76 $\pm$ 0.03*†††

637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

666